GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spago Nanomedical AB (OSTO:SPAGO) » Definitions » Return-on-Tangible-Asset

Spago Nanomedical AB (OSTO:SPAGO) Return-on-Tangible-Asset : -65.91% (As of Jun. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Spago Nanomedical AB Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Spago Nanomedical AB's annualized Net Income for the quarter that ended in Jun. 2024 was kr-32.61 Mil. Spago Nanomedical AB's average total tangible assets for the quarter that ended in Jun. 2024 was kr49.48 Mil. Therefore, Spago Nanomedical AB's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2024 was -65.91%.

The historical rank and industry rank for Spago Nanomedical AB's Return-on-Tangible-Asset or its related term are showing as below:

OSTO:SPAGO' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -123.41   Med: -57.17   Max: -35.19
Current: -82.16

During the past 13 years, Spago Nanomedical AB's highest Return-on-Tangible-Asset was -35.19%. The lowest was -123.41%. And the median was -57.17%.

OSTO:SPAGO's Return-on-Tangible-Asset is ranked worse than
73.13% of 1537 companies
in the Biotechnology industry
Industry Median: -39.41 vs OSTO:SPAGO: -82.16

Spago Nanomedical AB Return-on-Tangible-Asset Historical Data

The historical data trend for Spago Nanomedical AB's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spago Nanomedical AB Return-on-Tangible-Asset Chart

Spago Nanomedical AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -123.41 -83.54 -90.47 -64.49 -70.91

Spago Nanomedical AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -88.52 -85.79 -123.74 -65.75 -65.91

Competitive Comparison of Spago Nanomedical AB's Return-on-Tangible-Asset

For the Biotechnology subindustry, Spago Nanomedical AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spago Nanomedical AB's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spago Nanomedical AB's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Spago Nanomedical AB's Return-on-Tangible-Asset falls into.



Spago Nanomedical AB Return-on-Tangible-Asset Calculation

Spago Nanomedical AB's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-42.223/( (66.096+52.985)/ 2 )
=-42.223/59.5405
=-70.91 %

Spago Nanomedical AB's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jun. 2024 )  (Q: Mar. 2024 )(Q: Jun. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jun. 2024 )  (Q: Mar. 2024 )(Q: Jun. 2024 )
=-32.608/( (41.468+57.484)/ 2 )
=-32.608/49.476
=-65.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2024) net income data.


Spago Nanomedical AB  (OSTO:SPAGO) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Spago Nanomedical AB Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Spago Nanomedical AB's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Spago Nanomedical AB Business Description

Traded in Other Exchanges
N/A
Address
Scheelevagen 22, Lund, SWE, SE-223 63
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through previous detection of tumors and metastases. The Tumorad products focuses on the development of a completely new form of radionuclide therapy for tumor selective radiation therapy of cancer. The company development projects are based on a platform of polymeric materials with varoious properties for precise diagnosis and treatment of life threatening and debilitating diseases.

Spago Nanomedical AB Headlines

No Headlines